## UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1440, Alexandria, VA 22313-1450, on Alexandria, VA 22313-1450 Sir: Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of: EL721891987US Express Mail No. AVENTIS DOCKET NO.: DEAV2002/0065USNP INVENTORS: Mueller et al. TITLE: The Use of Saccharomyces cerevisiae erg4 Mutants For Expressing Mammalian Glucose Transporters **APPLICATION ELEMENTS** \*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) 2. Total Pages Specification 26 (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 3. Drawing(s) (35 U.S.C. 113) **Total Sheets** 4. Oath or Declaration **Total Pages** Unexecuted (original or copy) a. b. Copy from a prior application (37 CFR § 1.63(d)) **DELETION OF INVENTOR(S)** i. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). 5. Power of Attorney **Total Pages** Newly executed (original or copy) Copy from a prior application (37 CFR § 1.63(d)) 6. Microfiche Computer Program (Appendix)

Application Transmittal Letter Page 2

<b>7</b> .	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)									
	a. Computer Readable Copy									
	b. Paper Copy (identical to computer copy)									
	c. Statement verifying identity of above copies									
	o. Page Statement formying restricts of above sopies									
	If a CONTINUING Application, check appropriate box, and supply the requisite information:  Continuation Divisional Continuation-in-part of prior application no: , filed Examiner , Group/Art Unit  (The cross reference has been/will be inserted on page one of the specification).									
$\boxtimes$	This application claims the benefit of U.S. Provisional Application No. 60/455,340, filed March 17, 2003 and priority to German Patent Application No. 10242763.1 filed September 14, 2002. (The cross reference has been/will be inserted on page one of the specification).									
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior									
	application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
ACC	COMPANYING APPLICATION PARTS									
7.	Assignment Papers (cover sheet & document(s))									
8.	37 CFR §3.73(b) Statement (when there is an assignee)									
9.	Verified English Translation Document (if applicable)									
10.	Information Disclosure Copies of IDS Citations									
	Statement (IDS)/PTO-1449									
11.	Preliminary Amendment - 15 pages									
12.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)									
13.	*Small Entity Statement(s)  (PTO/SB/09-12)  Statement filed in prior application, Status still proper and desired									
14.	Certified Copy of Priority Document(s) DE 10242763.1  (if foreign priority is claimed)									
15.	Other: Application Data Sheet									
COF	RRESPONDENCE ADDRESS									
	Customer Number or Bar Code Label 005487									
	(Insert Customer No. or Attach bar code label bare)									
	Mill / HAL									
	William C. Coppola, Reg. No. 41,686									

Aventis Pharmaceuticals Inc. Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0065USNP

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CCC TO A NOMITTAL	Complete if Known				
FEE TRANSMITTAL	Application Number	To Be Assigned			
· =\/ 0000	Filing Date	Herewith			
for FY 2003	First Named Inventor	Mueller et al.			
Patent fees are subject to annual revision.	Examiner Name	To Be Assigned			
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit	To Be Assigned			
TOTAL AMOUNT OF PAYMENT (\$) 2,022.00	Attorney Docket No.	DEAV2002/0065 US NP			

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)									
Check _	] Money Order	Other	None	3. AD	OITID	NAL FE	ES							
Deposit Account						Large En		Small Er		_				
Deposit Account 18-1982					Fee Code	Fee (\$)	Fee Code	Fee (\$)						
Number Deposit											Fee Descriptio	n	Fee Paid	
Account Aventis Pharmaceuticals Inc.							130	2051	65		- late filing fee or			
The Commiss					1052	50	2052	25		- late provisional	filing fee or	}		
Charge fee(				redit any over		1053	130	1053	130	Non-Englis	Non-English Specification			
15 ' '		٠,٠		endency of this		1812	2,520	1812	2,520		request for reexa		<u> </u>	
to the above-ide				the filing fee	<u></u>	1804	920*	1804	920°	Examiner	g publication of S action	ark phor to		
	FE	E CAL	CULATI	ON		1805	1,840*	1805	1,840*	Requesting Examiner	g publication of S action	IR after		
1. BASIC FI						1251	110	2251	55		for reply within fir	rst month		
Large Entity Fee Fee	Small Fee	Entity Fee	Fee Des	crintian	Fee Paid	1252	410	2252	205	Extension	for reply within so	econd month		
Code (\$)	Code	(\$)												
1001 750	2001	375	Utility filir	-	750	1253 1254	930	2253 2254	465 725		for reply within th for reply within fo		<u> </u>	
1002 330 1003 520	2002	165 260	Design fil Plant filin			1254	1,450 1970	2255	985		for reply within fit			
1003 520	2003	375	Reissue	-	-	1401	320	2401	160			iai inonai		
1005 160	2005	80		al filing fee		1402	320	2402	160		ef in support of a	n anneai	<b> </b>	
			г			1403	280	2403	140		or oral hearing	парроаг		
2 EVIDA C		BTOTA		(\$)750.00		1451	1,510	1451	1,510	•	institute a public	IISE		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE						ł	·		·	proceeding	3			
}		Ex	tra	Fee from	Fee	1452	110	2452	55	Petition to	revive - unavoida	able		
o	44	_	aims 24 x	below	Paid = 432	1453	1,300	2453	650	Dotition to	revive - unintenti	ional	432432	
	=	L											102102	
L.	13	- 3**= [_	10 x	84	= 840	1501	1,300	2501	650	-	e fee (or reissue)	)		
Claims						1502	470 630	2502	235 315				<u> </u>	
Multiple Depende	ent				=	1503		2503 1460	130			202		
Large Entity	Í Smai	I Entity				1460 1807	130 50	1807	50		o the Commission elated to provision			
Fee Fee	Fee	Fee								application	ıs			
Code (\$) 1202 18	2202	( <b>\$</b> ) 9	Fee Des Claims in	cription excess of 20		1806	180	1806	180	Submission	n of Information	Disclosure		
1201 84	2201	42	independ	dent claims in	excess of 3	8021	40	8021	40	Recording	each patent ass			
1203 280	2203	140		dependent cla	im, if not	1809	750	2809	375	Filing a su	imes number of phonics in the second in the			
1204 84	2204	42		e independen		1810	750	2810	375		additional invention			
1205 18	2205	9		over original ¡ e claims in ex		1801	750	2801	375	Request for	(37 CFR § 1.129 or Continued Exa			
20 and over original patent						1802	900	1802	900		(RCE) Request for expedited examination of a			
SUBTOTAL (2) (\$)1272.00							(specify)			design ap				
300101AL (2) (3)1212.00						- Julier lee	(openiy)							
**or number previously paid, if greater; For Reissues, see above							d by Basi	: Filing Fe	e Paid		SUBTOTAL	(3) (5)		
SUBMITTED	BY			11	/		· · ·				Complete (If ap)	plicable)		
Name (Print/Type) William C. Copyola, Keg. No. 41,686								tration No	D.	41,686	Telephone	(908) 231-3	800	
l		111	11			Attom	ey/Agent)	1						

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Signature